Siltuximab (Mechanism of Action)

In this article, we will discuss Siltuximab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Siltuximab binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors IL-6 has been shown to be involved in diverse normal physiologic processes such as induction of immunoglobulin secretion. Overproduction of IL-6 has been linked to systemic manifestations in patients with MCD.

Pharmacodynamics

Cardiac Electrophysiology: The effect of multiple doses of Siltuximab (15 mg/kg every 3 weeks for 4 cycles) on the QTc interval was evaluated in an open label, single arm study in 30 patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma. No large changes in the mean QTc interval (i.e., >20 ms) were detected in the study. Measurement of IL-6 concentrations in serum or plasma during treatment should not be used as pharmacodynamic marker, as Siltuximab-neutralized antibody-IL-6 complexes interfere with current immunological-based IL-6 quantification methods.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.